ME01509B - Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti - Google Patents
Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnostiInfo
- Publication number
- ME01509B ME01509B MEP-2013-46A MEP4613A ME01509B ME 01509 B ME01509 B ME 01509B ME P4613 A MEP4613 A ME P4613A ME 01509 B ME01509 B ME 01509B
- Authority
- ME
- Montenegro
- Prior art keywords
- efficacy
- monitoring
- methods
- therapeutic use
- farnesyltransferase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62520404P | 2004-11-05 | 2004-11-05 | |
US70807505P | 2005-08-12 | 2005-08-12 | |
PCT/US2005/039948 WO2006052718A2 (en) | 2004-11-05 | 2005-11-02 | Farnesyltransferase inhibitors for treating sepsis |
EP05851365A EP1815247B1 (en) | 2004-11-05 | 2005-11-02 | Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ME01509B true ME01509B (me) | 2014-04-20 |
Family
ID=35840451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2013-46A ME01509B (me) | 2004-11-05 | 2005-11-02 | Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti |
Country Status (12)
Country | Link |
---|---|
US (3) | US20060111398A1 (me) |
EP (2) | EP1815247B1 (me) |
DK (2) | DK1815247T3 (me) |
ES (2) | ES2403060T3 (me) |
HK (1) | HK1110651A1 (me) |
HR (1) | HRP20130399T1 (me) |
ME (1) | ME01509B (me) |
PL (2) | PL2362218T3 (me) |
PT (2) | PT2362218E (me) |
RS (1) | RS52741B (me) |
SI (1) | SI2362218T1 (me) |
WO (1) | WO2006052718A2 (me) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | シヌクレイノパチーを治療する方法 |
US20050277629A1 (en) * | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
EP2370436A1 (en) * | 2008-11-13 | 2011-10-05 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
WO2010056985A2 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Treatment of proteinopathies using a farnesyl transferase inhibitor |
MX2015004784A (es) | 2012-10-16 | 2015-08-14 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t. |
WO2014062655A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt |
UY35084A (es) | 2012-10-16 | 2014-04-30 | Janssen Pharmaceutica Nv | MODULADORES DE RORyt DE QUINOLINILO UNIDOS POR METILENO |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Rorγtのアルキル結合キノリニルモジュレーター |
ES2742843T3 (es) | 2013-10-15 | 2020-02-17 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo de ROR(gamma)t |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
AU2015283811A1 (en) * | 2014-07-02 | 2017-02-09 | Bionomics Limited | Predictive biomarkers |
WO2016090107A2 (en) * | 2014-12-04 | 2016-06-09 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
DK3640345T3 (da) | 2015-08-17 | 2022-01-03 | Kura Oncology Inc | Fremgangsmåder til at behandle kræftpatienter med farnesyltransferaseinhibitorer |
CN105510187B (zh) * | 2016-01-28 | 2018-01-23 | 青岛啤酒股份有限公司 | 用于啤酒糖化过程中快速判定麦汁发酵度的方法 |
PL3534885T3 (pl) | 2016-11-03 | 2021-11-15 | Kura Oncology, Inc. | Inhibitory farnezylotransferazy do zastosowania w leczeniu nowotworu |
WO2021209473A1 (en) * | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Biphenyl derivatives |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6117432A (en) | 1995-04-20 | 2000-09-12 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
AU711142B2 (en) | 1995-12-08 | 1999-10-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
CN1095845C (zh) | 1996-12-20 | 2002-12-11 | "塔比法尔"有限责任公司 | 制取冻干的1β,10β-环氧-13-二甲基氨基-愈创-3(4)-烯-6,12-内酯盐酸盐的方法和装置 |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
GB2323783A (en) | 1997-04-02 | 1998-10-07 | Ferring Bv Group Holdings | Inhibitors of farnesyl protein transferase |
PL190944B1 (pl) | 1997-04-25 | 2006-02-28 | Janssen Pharmaceutica Nv | Pochodna chinazolinonu i sposób jej wytwarzania oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
AU747379B2 (en) | 1998-03-05 | 2002-05-16 | Formula One Management Limited | Data communication system |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
SK285231B6 (sk) | 1998-07-06 | 2006-09-07 | Janssen Pharmaceutica N. V. | Použitie 6-[(imidazol-5-yl)metyl]chinolínovej zlúčeniny na prípravu farmaceutickej kompozície na liečbu artropatie |
SK2442001A3 (en) | 1998-08-27 | 2002-10-08 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof |
CA2341739C (en) | 1998-08-27 | 2005-07-12 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
EA004542B1 (ru) | 1998-12-23 | 2004-06-24 | Янссен Фармацевтика Н.В. | 1, 2-аннелированные производные хинолина |
GB0023915D0 (en) | 2000-09-29 | 2000-11-15 | Inst Of Ophthalmology | Treatment of neuroinflammatory disease |
AU2002218311A1 (en) | 2000-11-28 | 2002-06-11 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
WO2002085364A1 (en) | 2001-04-25 | 2002-10-31 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating cachexia |
US20040096917A1 (en) * | 2002-11-12 | 2004-05-20 | Becton, Dickinson And Company | Diagnosis of sepsis or SIRS using biomarker profiles |
-
2005
- 2005-11-02 DK DK05851365.6T patent/DK1815247T3/da active
- 2005-11-02 EP EP05851365A patent/EP1815247B1/en active Active
- 2005-11-02 ME MEP-2013-46A patent/ME01509B/me unknown
- 2005-11-02 PL PL11158145T patent/PL2362218T3/pl unknown
- 2005-11-02 US US11/265,445 patent/US20060111398A1/en not_active Abandoned
- 2005-11-02 PT PT111581450T patent/PT2362218E/pt unknown
- 2005-11-02 WO PCT/US2005/039948 patent/WO2006052718A2/en active Application Filing
- 2005-11-02 ES ES05851365T patent/ES2403060T3/es active Active
- 2005-11-02 DK DK11158145.0T patent/DK2362218T3/en active
- 2005-11-02 RS RS20130146A patent/RS52741B/en unknown
- 2005-11-02 SI SI200531911T patent/SI2362218T1/sl unknown
- 2005-11-02 PL PL05851365T patent/PL1815247T3/pl unknown
- 2005-11-02 PT PT58513656T patent/PT1815247E/pt unknown
- 2005-11-02 EP EP11158145.0A patent/EP2362218B1/en active Active
- 2005-11-02 ES ES11158145.0T patent/ES2522830T3/es active Active
-
2008
- 2008-02-05 HK HK08101410.2A patent/HK1110651A1/xx unknown
-
2009
- 2009-02-02 US US12/363,810 patent/US20110195419A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,200 patent/US20120196766A1/en not_active Abandoned
-
2013
- 2013-05-08 HR HRP20130399TT patent/HRP20130399T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US20110195419A1 (en) | 2011-08-11 |
PL2362218T3 (pl) | 2015-02-27 |
EP2362218A2 (en) | 2011-08-31 |
SI2362218T1 (sl) | 2014-12-31 |
DK2362218T3 (en) | 2014-11-17 |
PL1815247T3 (pl) | 2013-08-30 |
US20060111398A1 (en) | 2006-05-25 |
HK1110651A1 (en) | 2008-07-18 |
ES2522830T3 (es) | 2014-11-18 |
ES2403060T3 (es) | 2013-05-13 |
PT1815247E (pt) | 2013-04-23 |
PT2362218E (pt) | 2014-12-04 |
US20120196766A1 (en) | 2012-08-02 |
WO2006052718A3 (en) | 2007-06-28 |
DK1815247T3 (da) | 2013-03-11 |
HRP20130399T1 (hr) | 2013-06-30 |
EP2362218B1 (en) | 2014-08-27 |
RS52741B (en) | 2013-08-30 |
WO2006052718A2 (en) | 2006-05-18 |
EP2362218A3 (en) | 2011-10-26 |
EP1815247A2 (en) | 2007-08-08 |
WO2006052718A8 (en) | 2007-02-08 |
EP1815247B1 (en) | 2013-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130399T1 (hr) | Terapeutska upotreba inhibitora farenziltransferaze i postupci praä†enja njihove efikasnosti | |
EP1763490A4 (en) | ELECTRODEIONIZATION DEVICE AND USE METHOD | |
IL213843A0 (en) | 4-aminotetracyclines and methods of use thereof | |
EP1942815A4 (en) | MEDICAL INSTALLATION TOOL AND APPLICATION METHOD THEREFOR | |
HK1103370A1 (en) | Respiratory devices and methods of use | |
IL176958A0 (en) | Compounds and methods of use | |
EP1793747A4 (en) | IMPROVED ULTRASONIC CATHETER DEVICES AND METHOD | |
EP1827391A4 (en) | DOSAGE FORMS AND METHODS OF USE THEREOF | |
EP1913112A4 (en) | SUPPORTING AGENT AND METHODS OF USE | |
EP2091588A4 (en) | CARDIAL DEVICE AND USE METHOD THEREFOR | |
IL190055A0 (en) | Quinolines and their therapeutic use | |
ZA200609445B (en) | Flow monitoring devices and methods of use | |
EP1906976A4 (en) | THERAPEUTIC POLYMERS AND METHODS OF USE | |
IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
EP1909689A4 (en) | IMPLANTS CONTAINING A MEDICAMENT AND METHOD OF USE | |
IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
IL179333A0 (en) | Monitoring the efficacy of fluid resuscitation | |
EP1812451A4 (en) | COMPOUNDS AND METHODS OF USE THEREOF | |
EP1736173A4 (en) | MEANS FOR THE TREATMENT OF TISSUE DAMAGE AND THERAPEUTIC PROCEDURE | |
GB0421164D0 (en) | Medical devices and methods of making medical devices | |
EP1894572A4 (en) | THERAPEUTIC AND / OR PROPHYLACTIC AGGREGATE AGAINST NEUROGENIC PAIN | |
EP1802737A4 (en) | TISSUE SYSTEM AND USE METHOD | |
EP1804880A4 (en) | MEDICAL DEVICES AND METHODS OF PREPARATION AND USE | |
IL185575A0 (en) | Benzoxazocines and their therapeutic use | |
GB0411145D0 (en) | Protease inhibitors and their therapeutic applications |